ATP2C1 blockers(ATPase secretory pathway Ca2+ transporting 1 blockers), GLRA1 agonists(glycine receptor alpha 1 agonists), GRIA1 antagonists(glutamate ionotropic receptor AMPA type subunit 1 antagonists)

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication-

Originator Organization

Baxter International, Inc.

Active Organization

Baxter Healthcare Corp.

Baxter International, Inc.Baxter Healthcare Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (18 Sep 1992),

Anesthesia

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC3H2F6O

InChIKeyDPYMFVXJLLWWEU-UHFFFAOYSA-N

CAS Registry57041-67-5

341

Clinical Trials associated with Desflurane

NCT07295158

/ Not yet recruitingNot ApplicableIIT

Laparoscopic Cholecystectomy Patients: Effect of Sevoflurane vs. Desflurane on Mechanical Power - A Prospective, Randomized, Controlled Trial

This single-center, prospective, randomized, assessor-blinded clinical trial aims to compare the effects of sevoflurane and desflurane anesthesia on intraoperative mechanical power in adult patients undergoing elective laparoscopic cholecystectomy. Mechanical power will be measured at three standardized time points using a validated formula, and secondary outcomes include driving pressure values and early postoperative respiratory complications (desaturation, laryngospasm, bronchospasm, cough).

Start Date01 Jan 2026

Sponsor / Collaborator-

ChiCTR2500113587

/ Not yet recruitingNot ApplicableIIT

Comparison of Desflurane versus Propofol for general anesthesia in elderly frailty patients undergoing shoulder arthroscopic surgery: a prospective randomized study

Start Date01 Jan 2026

Sponsor / Collaborator

The First Hospital of Harbin Medical University

ChiCTR2500113342

/ Not yet recruitingPhase 4IIT

Comparison of ciprofol and volatile anesthetics on quality of recovery after abdominal surgery in elderly patients: a randomized controlled study.

Start Date01 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Desflurane

100 Translational Medicine associated with Desflurane

100 Patents (Medical) associated with Desflurane

2,797

Literatures (Medical) associated with Desflurane

01 Apr 2026·TALANTA

Investigation of ion formation generated by an easy-to-assemble dielectric barrier discharge plasma ionization source based on printed circuit boards

Article

Author: Haack, Alexander ; Röckrath, Daniel ; Nitschke, Alexander ; Hitzemann, Moritz ; Thoben, Christian ; Schaefer, Christoph ; Zimmermann, Stefan

This study presents a detailed investigation of a recently developed dielectric barrier discharge plasma ionization source based on printed circuit boards. Specifically, the reactant and product ions formed in positive and negative polarity, and the difference, when the analyte is guided through or bypasses the plasma of the developed plasma ionization source, were investigated. Therefore, the ionization source is coupled to a self-built ion mobility spectrometer coupled to a mass spectrometer to obtain detailed ion mobility and m/z information. As test compounds, 2-propanol, 2-butanol, 2-pentanol, 2-propanone, sevoflurane, desflurane, and dibutyl maleate were used. We identified the dominant reactant ion species as protonated water clusters (H⁺(H₂O)_n) in positive mode and nitrate clustered with nitric acid [Formula: see text] in negative mode, yielding well-defined ion chemistry conditions. When the analytes are directed through the plasma, there is no fragmentation due to soft ionization, but a significant change in plasma chemistry, e.g. the alcohols tested show a significant conversion to the corresponding ketones (by oxidative dehydrogenation), which was the dominant pathway when they were passed directly through the plasma.

01 Mar 2026·JOURNAL OF CLINICAL ANESTHESIA

Desflurane versus propofol for ambulatory surgery: A systematic review and meta-analysis

Review

Author: Zhang, Peng ; Zhuang, Jing ; Liu, Xin ; Hu, Wei

BACKGROUND:

This study aimed to evaluate the efficacy, side effects and recovery profile of two commonly used anesthetic agents, desflurane versus propofol, for maintaining general anesthesia in ambulatory surgery.

METHODS:

Studies compared propofol with desflurane in adult patients undergoing ambulatory surgery were included. The generalized pivotal method was used to estimate the median and variance of the ratios of means and standard deviations of recovery times, and these ratios were then pooled in a DerSimonian-Laird random-effects meta-analysis with Knapp-Hartung adjustment.

RESULTS:

Twenty-two studies with a total of 1504 adult participants were included in this review. Compared with propofol, desflurane significantly reduced early recovery times, with reductions of at least 9.1% in mean time and 4.2% in standard deviation (variability) (both based on the lower limit of the 99%CI), all significant after Benjamini-Hochberg (BH) correction. In contrast, no significant differences were observed for most intermediate and late recovery metrics. Desflurane increased the risk of in-hospital PONV (RR: 2.15, 95%CI: 1.12 to 4.11), and postoperative antiemetic rescue (RR: 2.59, 95%CI: 1.35 to 4.95), all significant after BH correction. The subgroup analysis indicated that adding N₂O to desflurane was associated with an increased incidence of in-hospital PONV compared with propofol plus N₂O.

CONCLUSIONS:

In ambulatory surgery, desflurane demonstrated faster early recovery, higher incidence of in-hospital PONV and antiemetic rescue, compared with propofol. The reductions in mean time and variability for early recovery with desflurane could potentially contribute to improved operating room efficiency and lower labor costs. Future studies are needed to confirm these findings.

01 Feb 2026·Current Opinion in Anesthesiology

Protecting clinician autonomy and patient safety within the climate debate: the case for desflurane in modern anaesthesia

Review

Author: Kleinberg, Robert L. ; Landoni, Giovanni ; Zacharowski, Kai ; Reinoso-Barbero, Francisco ; Jakobsson, Jan ; Kranke, Peter ; Rossi, Marco ; Marin, Laurentiu ; Sanders, Graeme

Purpose of review:

The anaesthesia community should play a more active role in shaping sustainable healthcare practices. Current environmental measures, such as the European Commission’s impending restriction on desflurane (an inhaled anaesthetic) from January 2026, risk unintended consequences for patient care and clinical autonomy.

Recent findings:

While desflurane’s high global warming potential (GWP) has been the central justification, GWP is an oversimplified metric that fails to reflect the transient atmospheric behaviour of short-lived gases like desflurane compared with long-lived gases like carbon dioxide (CO 2 ). Recent climate modelling shows desflurane’s impact on global temperature is negligible, reversible, and overstated by CO₂-equivalence comparisons. Clinically, desflurane offers significant advantages, including rapid, predictable emergence, particularly beneficial for high-risk patient groups, such as elderly, obese, paediatric, neurosurgical, and cardiac patients.

Summary:

Blanket restrictions undermine anaesthetists’ ability to tailor care, and limit training, resilience, and preparedness in the face of drug shortages. We urge policymakers to support anaesthetic diversity and protect desflurane’s availability where use is clinically justified. Sustainability efforts should focus on high-impact areas like energy use, equipment manufacturing, and waste, rather than eliminating valuable pharmacological options. Patient safety and evidence-based practice must remain central as we strive toward a more responsible, nuanced environmental approach in anaesthesia.

News (Medical) associated with Desflurane

02 Dec 2025

·www.businesswire.com

Fresenius Kabi Expands Operating Room Portfolio with New Simplist ® Prefilled Syringes

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced two new products in its Simplist® portfolio of ready-to-administer prefilled syringes: Simplist® Ephedrine Sulfate Injection, USP and Simplist® Succinylcholine Chloride Injection, USP. Both medications are used in anesthesia and critical care, and their introduction extends the Simplist line’s use into operating rooms, supporting clinicians with safe, efficient and reliable medication delivery. Fresenius Kabi has expanded its Simplist® ready-to-administer portfolio, introducing new presentations that extend its use into operating rooms and support clinicians in anesthesia and critical care. Simplist Succinylcholine Chloride Injection, USP, is a paralytic used in addition to general anesthesia for intubation and during mechanical ventilation in pediatric and adult patients. Simplist Ephedrine Sulfate Injection, USP is indicated for the treatment of clinically important hypotension (low blood pressure) during anesthesia. “As part of our commitment to simplify medication delivery and improve patient safety, the expansion of our Simplist portfolio into the operating room demonstrates how we’re supporting anesthesiologists and nurse anesthetists in their vital work,” said Arun Verma, president of Fresenius Kabi Region U.S. and member of the Executive Leadership Team at Fresenius Kabi AG. “These ready-to-administer medications are designed to help clinicians throughout the hospital by helping to reduce complexity, help minimize waste, and reduce the number of drug-preparation steps where errors can occur.” About the Products: Simplist Succinylcholine Chloride Injection, USP is available in 100 mg per 5 mL (20 mg per mL) and 200 mg per 10 mL (20 mg per mL) strengths. It offers an 18-month shelf life and is stored in a refrigerator at 36°F (2°C) to 46°F (8°C). The single dose prefilled syringes are stable for up to 14 days at room temperature without loss of potency. Simplist Ephedrine Sulfate Injection, USP is available in 25 mg per 5 mL (5 mg per mL) and 50 mg per 10 mL (5 mg per mL) presentations. It can be stored at room temperature and has a 24-month shelf life. Both prefilled syringes are manufactured and prepared by Fresenius Kabi, eliminating the need for assembly or dilution at the point of care to simplify medication administration, enhance workflow efficiency, and support best practices in medication administration safety. To learn more about Fresenius Kabi’s expanding manufacturing and other operations in the U.S., visit www.MoreInAmerica.com. IMPORTANT SAFETY INFORMATION Succinylcholine Chloride Injection, USP WARNING: VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST, AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS CONTRAINDICATIONS In patients with skeletal muscle myopathies In patients with known hypersensitivity to succinylcholine After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury In patients with a personal or familial history or suspected genetic susceptibility to malignant hyperthermia WARNINGS AND PRECAUTIONS Anaphylaxis: Severe anaphylactic reactions to neuromuscular blocking agents, including succinylcholine, have been reported. Some cases have been life-threatening and fatal. Take necessary precautions, such as the immediate availability of appropriate emergency treatment. Risk of Death due to Medication Errors: Unintended administration of Succinylcholine Chloride Injection may result in paralysis, respiratory arrest and death. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings. Hyperkalemia: Succinylcholine Chloride Injection may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia. Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies. Bradycardia: Intravenous bolus administration may result in profound bradycardia or, rarely asystole. The incidence is higher following a second dose of succinylcholine. Pretreatment with anticholinergic agents (e.g. atropine) may reduce the occurrence of bradyarrhythmias. ADVERSE REACTIONS Adverse reactions reported with succinylcholine are cardiac arrest, malignant hyperthermia, arrhythmias, bradycardia, tachycardia, hypertension, hypotension, hyperkalemia, prolonged respiratory depression or apnea. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Drugs that May Enhance the Neuromuscular Blocking Action of Succinylcholine: promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma cholinesterase activity. INDICATIONS AND USAGE Succinylcholine Chloride Injection is a depolarizing neuromuscular blocker indicated in adults and pediatric patients: As an adjunct to general anesthesia To facilitate tracheal intubation To provide skeletal muscle relaxation during surgery or mechanical ventilation This Important Safety Information does not include all the information needed to use Succinylcholine Chloride Injection, USP safely and effectively. Please see full prescribing information, including BOXED WARNING, for Succinylcholine Chloride Injection, USP 100 mg per 5 mL and 200 mg per 10 at www.fresenius-kabi.com/us. Ephedrine Sulfate Injection, USP WARNINGS AND PRECAUTIONS Pressor Effects with Concomitant Use with Oxytocic Drugs: Pressor effect of sympathomimetic pressor amines is potentiated. Tachyphylaxis and Tolerance: Repeated administration of ephedrine may cause tachyphylaxis. ADVERSE REACTIONS Most common adverse reactions during treatment: nausea, vomiting, and tachycardia. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Interactions that Augment Pressor Effect: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure. Interactions that Antagonize the Pressor Effect: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure. Guanethidine: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly. Rocuronium: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed. Epidural anesthesia: Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice. Theophylline: Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice. Cardiac glycosides: Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered ephedrine. INDICATIONS AND USAGE Ephedrine Sulfate Injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. This Important Safety Information does not include all the information needed to use Ephedrine Sulfate Injection, USP safely and effectively. Please see full prescribing information, for Ephedrine Sulfate Injection, USP at www.fresenius-kabi.com/us.” About Fresenius Kabi As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving essential medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is part of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. For more information, please visit www.fresenius-kabi.com/us. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn and Facebook. This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.

25 Jun 2024

·www.fiercehealthcare.com

Breathing better: Hospitals begin to phase out major pollutants in patient care

Each puff of a metered-dose inhaler expels a potent hydrofluorocarbon gas with upwards of 3,000 times the greenhouse warming potential of carbon dioxide. It is becoming more widely known that the healthcare sector is a significant contributor to greenhouse gas emissions, accounting for nearly 9% of the total in the U.S. But perhaps less recognized is that common substances routinely used in care—anesthetic gasses, even inhalers—are part of the problem. Digging into the science, the irony becomes obvious: The mechanisms for keeping patients safe during a procedure or an asthma attack are also poisoning the environment. Desflurane, a common inhaled anesthetic, has heat-trapping properties hundreds to thousands of times greater than carbon dioxide. Meanwhile, nitrous oxide, a sedative used in surgery, has a warming potential 273 times that of carbon dioxide and greatly damages the ozone layer, which is crucial to absorbing harmful radiation from the sun. Even metered-dose inhalers that contain a seemingly small amount of hydrofluorocarbon gas have been shown to contribute meaningfully to emissions. At the end of last month, a small group of safety net hospitals and municipal health departments joined a 10-month collaborative in an effort to test decarbonization interventions and measure their results. The cohort, led by the Institute for Healthcare Improvement, includes sustainability professionals, clinicians and other healthcare leaders across six states. Each organization is expected to pick an improvement project and will receive support from experts and peers to carry it out. “For safety net hospitals who deliver care on tight margins and serve patient populations disproportionately impacted by the effects of climate change, investing in lowering carbon emissions holds the potential to advance their mission, strategy, and financial health,” the IHI said in its request for applications. The last IHI decarbonization cohort wrapped up in December 2023. More than a dozen organizations participated in 16 quality improvement projects. More than half measured reductions either in waste or purchases of anesthetic gas. Several sites decommissioned central nitrous oxide and eliminated desflurane from their operating rooms. Fierce Healthcare spoke to some of the participants about what they were able to achieve. Thinking big by going small Nitrous oxide, commonly used in dentistry, can be stored in one of two ways: in large centralized tanks that deliver the gas to operating rooms through piping, or in portable cylinder tanks. Choosing between the two might seem inconsequential. Indeed, one benefit of a centralized system is having to change the tanks less often. However, several hospitals around the world recently discovered that between 75% and 95% of their nitrous oxide leaks out through the central piping before it ever reaches the patient, wasting resources and polluting the atmosphere. Addressing this waste was a goal for Northwell, which joined the last IHI decarbonization cohort. But to do so, the health system would need to figure out how the gas was being procured and used at its facilities. With more than 800 ambulatory sites and 20-odd hospitals, this would prove no small task. “When you’re as big as we are, that was quite a challenge,” Teresa Murray Amato, M.D., VP of Clinical Sustainability and Resource Stewardship and director of geriatric emergency medicine at Northwell Health, told Fierce Healthcare. Amato started by looking for allies—“probably the best way to start,” she said—such as the head of anesthesia at her own hospital, who was really interested in sustainability. “Try to go for the easiest first,” Amato said. As part of its emergency management work, Northwell works to ensure it has a three-day supply of essential resources. Keeping that in mind, Amato’s team decided to test if anesthesiologists would have enough nitrous oxide if they were to only use the portable tanks for three days. The clinicians recorded how long they used the gas and at what flow rates. That information and anecdotal conversations revealed the gas was being used very infrequently, and Amato’s team extrapolated the use and determined that decommissioning centralized nitrous oxide systems would not negatively impact clinical practice. Spreading awareness of the environmental harms also reduced nonessential uses of nitrous oxide. For Northwell, eliminating the large tanks didn't mean getting rid of nitrous oxide altogether, it just consolidates resources in a more practical way. There are some cost savings too, though not as great as the enormous benefits to the environment. Even if someone left a portable tank open by accident and it leaked entirely, the impact would be a fraction of that of a centralized tank, according to Amato. “It’s such a simple solution, but it’s a challenge in a very large, highly matrixed organization,” Amato said. Armed with the success from this project, the proof of concept is now helping fuel other similar projects forward. “Now, everybody wants to be the next one to go,” Amato noted. Northwell’s new goal is to have almost no central tanks by the end of 2024. The dark side of inhalers To expel the medication, each puff of a metered-dose inhaler relies on a hydrofluorocarbon gas, a potent greenhouse gas with upwards of 3,000 times the warming potential of carbon dioxide. This gas contributes to climate change, which can lead to events that worsen asthma and in turn further drive up the use of inhalers. Though each inhaler seems small, 144 million were prescribed in the U.S. alone in 2020. And three-quarters of those contained the gas. In England, metered-dose inhalers have been found to represent 3% of total National Health Service carbon emissions, equal to the carbon emissions from all the electricity used by the NHS. “They actually have a pretty substantial contribution to healthcare’s overall environmental impact,” Gregg Furie, M.D., medical director for climate and sustainability at Brigham and Women's Hospital, told Fierce Healthcare. Alternatives, like dry powder and soft mist inhalers, exist. This was an area Mass General Brigham wanted to tackle through the IHI collaborative. “We saw it as an opportunity to provide some structure to a project that we initially wanted to focus on,” Furie said. The health system leaned on the institute's staff to learn how to bring a range of diverse stakeholders to the table. “There are way more stakeholders than you think there are,” Jonathan Slutzman, medical director for environmental sustainability at Mass General Hospital, told Fierce Healthcare. The collaboration also offered regular check-ins and a framework for accountability, which forced momentum internally, Slutzman added. Their goal was to reduce the overall share of metered-dose inhalers that are prescribed and to shift to alternatives where possible. They also hoped to raise awareness of the environmental impact of certain inhalers within the organization. They don't yet have concrete data on the project's outcomes to share. “This is not something that many practitioners are aware of,” Furie noted. “We are the ones who ultimately prescribe these devices… this is something that we feel we have real agency to do something about.” While the shift to alternative inhalers across the U.S. has been slow, Furie expects that to begin to change. That shift is being partly driven by increased scrutiny of the patent process and high prescription costs at the federal level. Apart from provider-driven efforts to move away from metered-dose inhalers, other solutions need to come from industry innovations and policy reform, per Furie. The FDA is studying the challenges of developing inhalers with a lower warming potential—but Slutzman believes the agency can be doing more to protect sustainability. One could argue that environmental impact should be a part of evaluating the safety of a drug, he said. “FDA should be able to encourage or make it easier for drug delivery devices that we know are environmentally better,” Slutzman said. “That would enable us to prescribe better inhalers.” Centering climate as a broader priority The idea for the collaboration began when the Agency for Healthcare Research and Quality commissioned IHI to develop a primer on decarbonization. IHI sought input from an expert panel, collaborating with the National Academy of Medicine and Health Care Without Harm to co-design resources along the way. “There are more and more organizations engaging in this area, which is very exciting and it is very important to ensure there is no duplication of efforts,” IHI Director Bhargavi Sampath, MPH, told Fierce Healthcare. Afterwards, the organization wanted to put the primer into practice by way of a collaborative, intended to inspire leader engagement, boost teams’ confidence and skills and build will across departments. “It really takes a very big group of people to do this work,” said IHI Project Director Becka DeSmidt. Anyone looking for organizational buy-in on sustainability initiatives is advised to stress the potential for cost savings, the moral obligation to address the climate for patient health and that prioritizing such initiatives can help retain current or recruit future staff. “We’ve heard a lot from clinicians directly about how meaningful and engaging this work can be and clinician advocacy can be really powerful in helping an organization make these commitments,” DeSmidt told Fierce Healthcare. Two organizations participating in the collaborative successfully made the case for additional sustainability hires by leveraging the progress they were making on their projects as well as the cost savings they were seeing. Two others integrated clinical decarbonization metrics into their key performance indicators amid “the growing acceptance of integrating climate priorities into broader system strategies,” DeSmidt said. “Something we were really excited about was the promise of bringing climate more centrally into health system priorities,” Sampath echoed, “to advance some of the climate work that really needs to take place more locally at the frontline and with clinician leadership.”

02 Apr 2024

·www.prnewswire.com

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to support sustainability goals BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. During a typical anaesthetic procedure, less than five percent of the volatile anaesthetic agent delivered to a patient is absorbed and metabolised, leaving approximately 95 percent it to be exhaled. Continue Reading Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions SageTech's trusted gas-capture technology—which is currently used in human healthcare—works by capturing the waste anaesthetic agent breathed out during an operation by safely adsorbing it into a specially developed reusable capture canister. These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere. "As a leading provider of veterinary care, we have a responsibility to take climate action at scale and lead the way toward more sustainable practices," said Ellie West, RCVS and EBVS® European Specialist in Veterinary Anaesthesia and Analgesia, and Linnaeus Environmental Sustainability Lead. "Our innovative collaboration should help us take a significant step forward in our sustainability journey, aimed at contributing to a better future for the planet—and the people and pets who depend on it." A veterinary-industry first, Mars Veterinary Health's one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts. Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come. "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical. "It has been wonderful to work with the Linnaeus and Waltham teams, and we are confident this pilot project will demonstrate to the veterinary profession how such collaborations can be a collective force for good." This industry-first pilot in sustainable veterinary care is consistent with Mars, Incorporated's Net Zero Roadmap, a detailed action plan for achieving net zero greenhouse gas emissions by 2050, as well as details on the company's progress and history of working on climate action. Details about Mars, Incorporated's wider sustainability—including climate—work can be found in its Sustainable in a Generation Scorecard. About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS™. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai, VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinary.com. About Linnaeus Part of Mars Veterinary Health, Linnaeus is a highly respected community of more than 50 primary care and 17 referral veterinary practices based in the UK. Linnaeus employs over 6,000 pet-loving Associates with some of the country's finest vet and nursing teams who together are committed to excellence and delivering high-quality care to patients. Learn more at linnaeusgroup.co.uk. About Mars Science & Diagnostics Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Antech, our global veterinary diagnostics business, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software; reference laboratories; veterinary imaging and technology; education; and telemedicine with board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health. About SageTech Veterinary The manufacture of virgin anaesthetic agents and their release as waste volatile gases is highly damaging to the environment and contributes significantly to the total carbon footprint of healthcare. SageTech Veterinary is part of SageTech Medical, a medical device and pharmaceutical company focused on the research, design, manufacture, and distribution of technologies for the capture and recycling of waste volatile anaesthetic agents in human and animal healthcare. Their unique circular economy solution safely captures volatile anaesthetic agents (sevoflurane, isoflurane, desflurane) through actively controlled adsorption onto a reusable capture canister. Learn more at sagetechveterinary.com. Photo - SOURCE Mars PetCare

100 Deals associated with Desflurane

External Link

KEGG	Wiki	ATC	Drug Bank
D00546	Desflurane	N01AB07	DB01189

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	Baxter Healthcare Corp.	18 Sep 1992

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04805775 (not provided, Pubmed \| Sleep Med)	Not Applicable	Maintenance	118	Desflurane-based volatile anesthesia	zfqsugajby(oiwjgsvxpx) = dybrrxtcma kttlmmoimx (evlrgughov, 3.46)	Positive	01 Sep 2024
				Propofol-based total intravenous anesthesia	zfqsugajby(oiwjgsvxpx) = zkqulzoiil kttlmmoimx (evlrgughov, 3.16)
NCT02324283 (CTgov)	Not Applicable	Lung Cancer	80	desflurane (Desflurane)	sjdfgtnuxw(abbyluwttw) = tudztcgrnl bdsdbuyyjq (jccmevbzph, 12.0) View more	-	05 Apr 2024
				Propofol (Propofol)	sjdfgtnuxw(abbyluwttw) = jrnkyhiyfi bdsdbuyyjq (jccmevbzph, 11.3) View more
NCT04691128 (Pubmed \| BMC Anesthesiol)	Not Applicable	Supratentorial Neoplasms	110	Desflurane anesthesia	ocotlsqvna(hsigoeisek) = iewdpacfxi iwshfjudid (rmkkuymobf ) View more	-	10 Jan 2023
				desflurane anesthesia (Total intravenous anesthesia (TIVA))	ocotlsqvna(hsigoeisek) = awwlalgtby iwshfjudid (rmkkuymobf ) View more
NCT03996148 (CTgov)	Phase 4	Carotid Stenosis	21	Propofol+Desflurane+Remifentanil (Remifentanil, Propofol, and Desflurane)	vvzxhinkre(xkgxlnqjoq) = nhajzkgdoa kcfxmkzcoq (ennrtmfrff, 4) View more	-	06 Apr 2022
				Dexmedetomidine+Desflurane+Remifentanil (Remifentanil, Dexmedetomidine, and Desflurane)	vvzxhinkre(xkgxlnqjoq) = taphdjiath kcfxmkzcoq (ennrtmfrff, 4) View more
NCT02756715 (Pubmed \| Biomed Res Int)	Not Applicable	-	80	Desflurane group	yqdthaswqj(pxlzdurahe) = Pulmonary oxygenation was briefly improved after tourniquet deflation in the desflurane group but was similar between the two groups begging at 1 h, postoperatively tipddbijfg (hrxfdnmltd )	-	01 Jan 2021
				Propofol group
NCT03540030 (CTgov)	Phase 4	Osteoarthritis \| Osteonecrosis \| Rotator Cuff Tear Arthropathy	86	opioids (Observational)	bropqyjqiy(ozlfxighao) = qdtqftxqot ospfhcoxtt (sjisebbgot, pqfjksvnpi - batzzecuid) View more	-	12 Oct 2020
				regional block+acetaminophen+propofol+toradol+desflurane+sevoflurane+IV lidocaine+celecoxib+rocuronium+vecuronium+Gabapentin (Non-Opioid Intervention)	bropqyjqiy(ozlfxighao) = axdihxodgg ospfhcoxtt (sjisebbgot, ccxhobdfsa - ejopihrwye) View more
NCT02199314 (CTgov)	Not Applicable	Idiopathic scoliosis	30	desflurane	wspguscjnx(zfultzaxij) = ankucefsru vlporpemrv (avhzedzwsr, yqvhgmztvo - ianbxfbigf) View more	-	22 Sep 2020
NCT03029715 (CTgov)	Not Applicable	Obesity, Morbid	100	Dexmedetomidine+propofol+Remifentanil (Intravenous Anaesthesia)	tyyrolpsyw(kdhoihxjis) = jjpvqnoynd fciemedwhx (hgycbbnufd, skzpvhzxsx - jpqrqlksze) View more	-	16 Sep 2020
				desflurane+Remifentanil (Inhalation Anaesthesia)	tyyrolpsyw(kdhoihxjis) = bxyfnpnuij fciemedwhx (hgycbbnufd, dzsctwlqdh - laexxekfeh) View more
NCT02631525 (CTgov)	Phase 4	Anesthesia	40	Propofol (REM-PRO)	aenqpuieom(zanhbwojxt) = flckekiziz lplfgpljyl (olyrryhccy, hlgxwgzrik - rcjwqszong) View more	-	25 Aug 2020
				desflurane (REM-DES)	aenqpuieom(zanhbwojxt) = jbljgnijar lplfgpljyl (olyrryhccy, dsgytjapng - gtjyujaxyg) View more
NCT02922660 (Pubmed \| Chin Med J (Engl))	Not Applicable	Strabismus	200	Desflurane anesthesia	rnxaevjoly(mfwlppcnkt) = daafpcbqdl ocrakijrpx (wissyaaxka ) View more	-	05 Apr 2020
				Propofol-remifentanil anesthesia	rnxaevjoly(mfwlppcnkt) = wnvsudwbtf ocrakijrpx (wissyaaxka ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Desflurane

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation